{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:29:12Z","timestamp":1791584952903,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12144-8","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:39:20Z","timestamp":1781876360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges"],"prefix":"10.1007","volume":"53","author":[{"given":"Ali","family":"Shahin Baher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Ganjalikhani Hakemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armita","family":"Ganjalikhani Hakemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojdeh","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Saltanatpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey A.","family":"Zamyatnin Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazdak","family":"Ganjalikhani Hakemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"1","key":"12144_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/carcin\/bgp263","volume":"31","author":"MJ Thun","year":"2010","unstructured":"Thun MJ et al (2010) The global burden of cancer: priorities for prevention. Carcinogenesis 31(1):100\u2013110","journal-title":"Carcinogenesis"},{"issue":"8","key":"12144_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"12144_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM et al (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22(1):20","journal-title":"Mol Cancer"},{"key":"12144_CR4","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S et al (2025) CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol 16:1574742","journal-title":"Front Immunol"},{"issue":"4","key":"12144_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood cancer J 11(4):69","journal-title":"Blood cancer J"},{"issue":"10","key":"12144_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL (2018) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8(10):1219\u20131226","journal-title":"Cancer Discov"},{"issue":"2","key":"12144_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra A et al (2024) Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol 112(2):211\u2013222","journal-title":"Eur J Haematol"},{"issue":"7","key":"12144_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"M-E Goebeler","year":"2020","unstructured":"Goebeler M-E, Bargou RC (2020) T cell-engaging therapies\u2014BiTEs and beyond. Nat Reviews Clin Oncol 17(7):418\u2013434","journal-title":"Nat Reviews Clin Oncol"},{"issue":"8","key":"12144_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF et al (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discovery 18(8):585\u2013608","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"12144_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat reviews Clin Oncol 17(3):147\u2013167","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"12144_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X et al (2019) Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol 12(1):128","journal-title":"J Hematol Oncol"},{"issue":"1","key":"12144_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC et al (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31(1):71\u201375","journal-title":"Nat Biotechnol"},{"key":"12144_CR13","doi-asserted-by":"publisher","first-page":"108587","DOI":"10.1016\/j.intimp.2022.108587","volume":"106","author":"H Ebrahimiyan","year":"2022","unstructured":"Ebrahimiyan H et al (2022) Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol 106:108587","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"12144_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L et al (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21(10):1089\u20131108","journal-title":"Cell Mol Immunol"},{"issue":"22","key":"12144_CR15","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","volume":"4","author":"R Basar","year":"2020","unstructured":"Basar R, Daher M, Rezvani K (2020) Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv 4(22):5868\u20135876","journal-title":"Blood Adv"},{"issue":"8","key":"12144_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani K et al (2017) Engineering natural killer cells for cancer immunotherapy. Mol Ther 25(8):1769\u20131781","journal-title":"Mol Ther"},{"issue":"10","key":"12144_CR17","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ et al (2018) Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24(10):1504\u20131506","journal-title":"Nat Med"},{"issue":"1","key":"12144_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J et al (2019) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25(1):82\u201388","journal-title":"Nat Med"},{"issue":"9","key":"12144_CR19","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker AJ et al (2017) Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther 25(9):2189\u20132201","journal-title":"Mol Ther"},{"issue":"1","key":"12144_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328","journal-title":"Nat Med"},{"issue":"1","key":"12144_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK et al (2021) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12(1):868","journal-title":"Nat Commun"},{"issue":"6","key":"12144_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat reviews Clin Oncol 20(6):359\u2013371","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"12144_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS et al (2018) Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat reviews Clin Oncol 15(1):47\u201362","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"12144_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","volume":"12","author":"T Rabilloud","year":"2021","unstructured":"Rabilloud T et al (2021) Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun 12(1):865","journal-title":"Nat Commun"},{"key":"12144_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2021.07.002","volume":"100","author":"W Liao","year":"2021","unstructured":"Liao W et al (2021) Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia. Exp Hematol 100:1\u201311","journal-title":"Exp Hematol"},{"issue":"12","key":"12144_CR26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282\u20131295","journal-title":"Cancer Discov"},{"issue":"7750","key":"12144_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M et al (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568(7750):112\u2013116","journal-title":"Nature"},{"issue":"10","key":"12144_CR28","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M et al (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24(10):1499\u20131503","journal-title":"Nat Med"},{"issue":"7","key":"12144_CR29","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Sch\u00f6nfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N (2013) TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids 2(7):e105","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"12144_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT et al (2016) Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164(4):770\u2013779","journal-title":"Cell"},{"key":"12144_CR31","doi-asserted-by":"publisher","first-page":"1490911","DOI":"10.3389\/fimmu.2024.1490911","volume":"15","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Smith R (2024) Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol 15:1490911","journal-title":"Front Immunol"},{"issue":"215","key":"12144_CR32","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"V Fedorov","year":"2013","unstructured":"Fedorov V, Themeli M, Sadelain M (2013) PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5(215):215ra172 Epub 2013\/12\/18","journal-title":"Sci Transl Med"},{"issue":"567","key":"12144_CR33","doi-asserted-by":"publisher","first-page":"eabf2636","DOI":"10.1126\/scitranslmed.abf2636","volume":"12","author":"B Gy\u00f6rgy","year":"2020","unstructured":"Gy\u00f6rgy B (2020) Bispecific CAR T cells have a dual grasp on tumors. Sci Transl Med 12(567):eabf2636","journal-title":"Sci Transl Med"},{"issue":"11","key":"12144_CR34","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","volume":"21","author":"M Hegde","year":"2013","unstructured":"Hegde M et al (2013) Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21(11):2087\u20132101","journal-title":"Mol Ther"},{"issue":"10","key":"12144_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X et al (2020) Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135(10):713\u2013723","journal-title":"Blood"},{"issue":"9","key":"12144_CR36","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/cancers12092523","volume":"12","author":"RJ Cronk","year":"2020","unstructured":"Cronk RJ, Zurko J, Shah NN (2020) Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers 12(9):2523","journal-title":"Cancers"},{"issue":"2","key":"12144_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S et al (2024) CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood 143(2):118\u2013123","journal-title":"Blood"},{"issue":"7","key":"12144_CR38","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","volume":"31","author":"E Kokalaki","year":"2023","unstructured":"Kokalaki E et al (2023) Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Mol Ther 31(7):2089\u20132104","journal-title":"Mol Ther"},{"key":"12144_CR39","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S G\u00f3mez-Melero","year":"2025","unstructured":"G\u00f3mez-Melero S, Hassouneh F, Vallejo-Berm\u00fadez IM, Ag\u00fcera-Morales E, Solana R, Caballero-Villarraso J (2025) Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol 16:1546172","journal-title":"Front Immunol"},{"issue":"1","key":"12144_CR40","doi-asserted-by":"publisher","first-page":"vdac185","DOI":"10.1093\/noajnl\/vdac185","volume":"5","author":"A Schmidts","year":"2023","unstructured":"Schmidts A et al (2023) Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma. Neuro-Oncology Adv 5(1):vdac185","journal-title":"Neuro-Oncology Adv"},{"issue":"2","key":"12144_CR41","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.xcrm.2024.101422","volume":"5","author":"JT Zoine","year":"2024","unstructured":"Zoine JT, Immadisetty K, Ibanez-Vega J, Moore SE, Nevitt C, Thanekar U, Tian L, Karouni A, Chockley PJ, Arthur B, Sheppard H, Klco JM, Langfitt DM, Krenciute G, Gottschalk S, Babu MM, Velasquez MP (2024) Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. Cell Rep Med 5(2):101422","journal-title":"Cell Rep Med"},{"issue":"3","key":"12144_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","volume":"11","author":"R Dannenfelser","year":"2020","unstructured":"Dannenfelser R et al (2020) Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst 11(3):215\u2013228e5","journal-title":"Cell Syst"},{"issue":"7","key":"12144_CR43","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/biomedicines10071493","volume":"10","author":"C Moreno","year":"2022","unstructured":"Moreno C et al (2022) Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. Biomedicines 10(7):1493","journal-title":"Biomedicines"},{"issue":"8","key":"12144_CR44","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri M et al (2016) Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J 6(8):e458","journal-title":"Blood Cancer J"},{"key":"12144_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S et al (2019) Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev 12:145\u2013156","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"591","key":"12144_CR46","doi-asserted-by":"publisher","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A et al (2021) SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med 13(591):eabd8836","journal-title":"Sci Transl Med"},{"issue":"1","key":"12144_CR47","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41467-020-20671-6","volume":"12","author":"S Park","year":"2021","unstructured":"Park S et al (2021) Direct control of CAR T cells through small molecule-regulated antibodies. Nat Commun 12(1):710","journal-title":"Nat Commun"},{"issue":"3","key":"12144_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"WR Strohl","year":"2019","unstructured":"Strohl WR, Naso M (2019) Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies 8(3):41","journal-title":"Antibodies"},{"issue":"12","key":"12144_CR49","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/cancers17121945","volume":"17","author":"T Sanomachi","year":"2025","unstructured":"Sanomachi T, Katsuya Y, Nakatsura T, Koyama T, Next-Generation CAR-T (2025) TCR-T cell therapies for solid tumors: innovations, challenges, and global development trends. Cancers (Basel) 17(12):1945","journal-title":"Cancers (Basel)"},{"issue":"1","key":"12144_CR50","doi-asserted-by":"publisher","first-page":"11483","DOI":"10.1038\/srep11483","volume":"5","author":"J Han","year":"2015","unstructured":"Han J et al (2015) CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 5(1):11483","journal-title":"Sci Rep"},{"issue":"1","key":"12144_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12672-025-04276-3","volume":"17","author":"OQB Allela","year":"2025","unstructured":"Allela OQB, Shareef A, Jyothi SR, Nayak PP, Janney JB, Singh G, Chauhan AS, Oripov F, Sameer HN, Yaseen A, Salih RM, Adil M (2025) Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance. Discov Oncol 17(1):113","journal-title":"Discov Oncol"},{"issue":"1","key":"12144_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","volume":"14","author":"H Lin","year":"2024","unstructured":"Lin H et al (2024) Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control. Blood cancer J 14(1):98","journal-title":"Blood cancer J"},{"issue":"10","key":"12144_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41422-023-00828-w","volume":"33","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Sadelain M (2023) CAR T cell design: approaching the elusive AND-gate. Cell Res 33(10):739\u2013740","journal-title":"Cell Res"},{"issue":"2","key":"12144_CR54","doi-asserted-by":"publisher","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","volume":"33","author":"L Abdo","year":"2025","unstructured":"Abdo L, Batista-Silva LR, Bonamino MH (2025) Cost-effective strategies for CAR-T cell therapy manufacturing. Mol Ther Oncol 33(2):200980","journal-title":"Mol Ther Oncol"},{"issue":"2","key":"12144_CR55","doi-asserted-by":"publisher","first-page":"e20230903","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M et al (2024) CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med 221(2):e20230903","journal-title":"J Exp Med"},{"issue":"11","key":"12144_CR56","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","volume":"43","author":"A Biederst\u00e4dt","year":"2025","unstructured":"Biederst\u00e4dt A, Rezvani K (2025) Engineered natural killer cells for cancer therapy. Cancer Cell 43(11):1987\u20132013","journal-title":"Cancer Cell"},{"issue":"6","key":"12144_CR57","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u2013553","journal-title":"N Engl J Med"},{"issue":"1","key":"12144_CR58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV et al (2025) The clinical landscape of CAR NK cells. Exp Hematol Oncol 14(1):46","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"12144_CR59","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jcyt.2025.06.006","volume":"27","author":"S Rana","year":"2025","unstructured":"Rana S, Thomas L, Kirkham AM, Shorr R, Visram A, Maganti H, Seftel M, Allan DS (2025) CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials. Cytotherapy 27(10):1179\u20131189","journal-title":"Cytotherapy"},{"key":"12144_CR60","doi-asserted-by":"publisher","first-page":"104912","DOI":"10.1016\/j.critrevonc.2025.104912","volume":"214","author":"F Zhang","year":"2025","unstructured":"Zhang F, Soleimani Samarkhazan H, Pooraskari Z, Bayani A, Beyond (2025) CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy. Crit Rev Oncol Hematol 214:104912","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"12144_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W et al (2024) Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discovery 10(1):40","journal-title":"Cell Death Discovery"},{"issue":"1","key":"12144_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T et al (2024) Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int 24(1):133","journal-title":"Cancer Cell Int"},{"key":"12144_CR63","doi-asserted-by":"publisher","first-page":"1087155","DOI":"10.3389\/fimmu.2023.1087155","volume":"14","author":"P Rascle","year":"2023","unstructured":"Rascle P et al (2023) NK cell education: Physiological and pathological influences. Front Immunol 14:1087155","journal-title":"Front Immunol"},{"issue":"17","key":"12144_CR64","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/cells13171464","volume":"13","author":"V Im\u0161irovi\u0107","year":"2024","unstructured":"Im\u0161irovi\u0107 V et al (2024) Maintaining the balance: regulation of NK cell activity. Cells 13(17):1464","journal-title":"Cells"},{"issue":"1","key":"12144_CR65","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","volume":"13","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A et al (2020) Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol 13(1):168","journal-title":"J Hematol Oncol"},{"issue":"1","key":"12144_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/immuno5010009","volume":"5","author":"E Boneva","year":"2025","unstructured":"Boneva E, Shivarov V, Ivanova M (2025) A Concise Review of the Role of the NKG2D Receptor and Its Ligands in Cancer. Immuno 5(1):9","journal-title":"Immuno"},{"issue":"8","key":"12144_CR67","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.ymthe.2024.06.034","volume":"32","author":"Y Gong","year":"2024","unstructured":"Gong Y et al (2024) NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. Mol Ther 32(8):2711\u20132727","journal-title":"Mol Ther"},{"issue":"1","key":"12144_CR68","doi-asserted-by":"publisher","first-page":"10555","DOI":"10.1038\/s41598-023-37779-6","volume":"13","author":"M Kaulfuss","year":"2023","unstructured":"Kaulfuss M et al (2023) The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells. Sci Rep 13(1):10555","journal-title":"Sci Rep"},{"key":"12144_CR69","doi-asserted-by":"publisher","first-page":"1199594","DOI":"10.3389\/fimmu.2023.1199594","volume":"14","author":"M Campos-Mora","year":"2023","unstructured":"Campos-Mora M et al (2023) NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells. Front Immunol 14:1199594","journal-title":"Front Immunol"},{"issue":"6","key":"12144_CR70","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3892\/ol.2023.13822","volume":"25","author":"H Kim","year":"2023","unstructured":"Kim H et al (2023) CD19\/CD22 bispecific chimeric antigen receptor\u2013NK\u201392 cells are developed and evaluated. Oncol Lett 25(6):236","journal-title":"Oncol Lett"},{"issue":"1","key":"12144_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","volume":"22","author":"F Ramezani","year":"2023","unstructured":"Ramezani F et al (2023) Outsmarting trogocytosis to boost CAR NK\/T cell therapy. Mol Cancer 22(1):183","journal-title":"Mol Cancer"},{"issue":"8","key":"12144_CR72","doi-asserted-by":"publisher","first-page":"100677","DOI":"10.1016\/j.medj.2025.100677","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L (2025) Emerging trends in clinical allogeneic CAR cell therapy. Med 6(8):100677","journal-title":"Med"},{"key":"12144_CR73","doi-asserted-by":"publisher","first-page":"1603757","DOI":"10.3389\/fimmu.2025.1603757","volume":"16","author":"FD dos Reis","year":"2025","unstructured":"dos Reis FD, Saidani Y, Mart\u00edn-Rubio P, Sanz-Pamplona R, Stojanovic A, Correia MP (2025) CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy. Front Immunol 16:1603757","journal-title":"Front Immunol"},{"issue":"6","key":"12144_CR74","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.7150\/ijbs.108036","volume":"21","author":"Z Wang","year":"2025","unstructured":"Wang Z et al (2025) From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy. Int J Biol Sci 21(6):2676\u20132691","journal-title":"Int J Biol Sci"},{"issue":"1","key":"12144_CR75","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J (2024) Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov 10(1):318","journal-title":"Cell Death Discov"},{"key":"12144_CR76","doi-asserted-by":"publisher","first-page":"1550652","DOI":"10.3389\/fimmu.2025.1550652","volume":"16","author":"J-H Guo","year":"2025","unstructured":"Guo J-H et al (2025) Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. Front Immunol 16:1550652","journal-title":"Front Immunol"},{"key":"12144_CR77","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","volume":"65","author":"A Viardot","year":"2018","unstructured":"Viardot A, Bargou R (2018) Bispecific antibodies in haematological malignancies. Cancer Treat Rev 65:87\u201395","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"12144_CR78","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"issue":"1","key":"12144_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"8","key":"12144_CR80","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"8","key":"12144_CR81","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s12325-024-02842-9","volume":"41","author":"LJ Costa","year":"2024","unstructured":"Costa LJ, Rodriguez-Otero P (2024) Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023\u2014A Podcast. Adv Therapy 41(8):3017\u20133027","journal-title":"Adv Therapy"},{"issue":"1","key":"12144_CR82","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K et al (2017) CAR T cell therapy for solid tumors. Annu Rev Med 68(1):139\u2013152","journal-title":"Annu Rev Med"},{"issue":"26","key":"12144_CR83","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375(26):2561\u20132569","journal-title":"N Engl J Med"},{"issue":"9","key":"12144_CR84","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12032-025-02957-1","volume":"42","author":"H Bharadia","year":"2025","unstructured":"Bharadia H et al (2025) CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions. Med Oncol 42(9):410","journal-title":"Med Oncol"},{"issue":"4","key":"12144_CR85","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843\u2013851","journal-title":"Mol Ther"},{"key":"12144_CR86","doi-asserted-by":"publisher","first-page":"1166038","DOI":"10.3389\/fimmu.2023.1166038","volume":"14","author":"MK Kilgour","year":"2023","unstructured":"Kilgour MK et al (2023) Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol 14:1166038","journal-title":"Front Immunol"},{"issue":"3","key":"12144_CR87","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S et al (2020) Off-the-shelf\u2019allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery 19(3):185\u2013199","journal-title":"Nat Rev Drug Discovery"},{"issue":"20","key":"12144_CR88","first-page":"2470","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie C et al (2023) Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood. J Am Soc Hematol 141(20):2470\u20132482","journal-title":"J Am Soc Hematol"},{"issue":"2","key":"12144_CR89","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S et al (2023) Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 29(2):422\u2013429","journal-title":"Nat Med"},{"issue":"1","key":"12144_CR90","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41408-024-01081-z","volume":"14","author":"MJ Rees","year":"2024","unstructured":"Rees MJ et al (2024) Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood cancer J 14(1):122","journal-title":"Blood cancer J"},{"issue":"11","key":"12144_CR91","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"12144_CR92","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.3390\/curroncol30090619","volume":"30","author":"R Alsajjan","year":"2023","unstructured":"Alsajjan R, Mason WP (2023) Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update. Curr Oncol 30(9):8501\u20138549","journal-title":"Curr Oncol"},{"issue":"8","key":"12144_CR93","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/biom14081035","volume":"14","author":"W Li","year":"2024","unstructured":"Li W et al (2024) CAR-NK cell therapy: a transformative approach to overcoming oncological challenges. Biomolecules 14(8):1035","journal-title":"Biomolecules"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12144-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:02:19Z","timestamp":1781881339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12144-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12144"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12144-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors used artificial intelligence tools, including Bing and GPT 4, to improve and refine the language during the preparation of this article. These tools were employed to ensure alignment with academic standards while enhancing readability for a broader audience. After utilizing these tools, the authors reviewed and revised the entire manuscript and took full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"963"}}